St. John's Wort

Overview

Hypericum perforatum (family Hypericaceae) is a perennial herb native to Europe and western Asia, now widely naturalised across temperate regions worldwide. Its common name derives from the traditional harvest around St. John's Day (June 24), when the plant blooms. The "perforatum" epithet refers to the translucent secretory gland-like oil dots visible in leaves when held to light — these are lysigenous secretory ducts containing phloroglucinol derivatives including the primary active compound, hyperforin.

Traditional use spans over 2,000 years: Hippocrates, Paracelsus, and Culpeper all described uses for wound healing, anxiety, nerve pain, and melancholy — a traditional use that aligns closely with modern pharmacological understanding. St. John's Wort is the best-selling botanical antidepressant in Europe, particularly Germany, where it outsells synthetic antidepressants and is licensed as a prescription medicine for mild-moderate depression.

The two key active constituents are mechanistically distinct. Hyperforin (phloroglucinol derivative, 2–5% in dried aerial parts) is the primary antidepressant compound — a non-selective monoamine reuptake inhibitor via TRPC6 activation, chemically unstable (oxidises rapidly in air and light), explaining why unstabilised OTC products show inconsistent efficacy. Hypericin (naphthodianthrone, 0.1–0.3%) is a weak MAO-A/B inhibitor and photosensitiser. Standardised extracts — LI 160 (0.3% hypericin) and WS 5570 (0.3% hypericin + 3% hyperforin) — are pharmacologically superior to unstabilised preparations, and results across preparations are not interchangeable.

Mechanism of Action

Hyperforin — TRPC6 Channel-Mediated Multi-Transmitter Reuptake Inhibition

  Hyperforin (lipophilic phloroglucinol)
        │
        ▼
  TRPC6 (Transient Receptor Potential Canonical 6)
  — sodium-permeable non-selective cation channel —
        │
        ▼
  Na+ influx → presynaptic terminal depolarisation
        │
        ▼
  Electrochemical gradient collapse
  (VMAT2, SERT, DAT, NET all Na+-gradient dependent)
        │
        ├── SERT inhibited  →  ↑ synaptic serotonin (5-HT)
        ├── DAT inhibited   →  ↑ synaptic dopamine (DA)
        ├── NET inhibited   →  ↑ synaptic norepinephrine (NE)
        ├── GABA-T inhibited →  ↑ synaptic GABA
        └── Glu transporter  →  ↑ synaptic glutamate

This mechanism is unique among antidepressants, discovered by Müller et al. (2001) and confirmed by Leuner et al. (2007). It contrasts sharply with SSRIs (selective SERT only), SNRIs (SERT + NET), and TCAs (SERT + NET + receptor blockade). No other licensed antidepressant inhibits all five neurotransmitter systems simultaneously via a single upstream ion channel mechanism.

1. TRPC6 activation: Hyperforin potently activates TRPC6 — a sodium-permeable, non-selective cation channel expressed at presynaptic terminals throughout the brain
2. Na+ influx: TRPC6 opening → Na+ influx into the presynaptic terminal → membrane depolarisation, raising intracellular [Na+]
3. Gradient collapse for all monoamine transporters: VMAT2 and plasma membrane transporters (SERT, DAT, NET) depend on the transmembrane Na+ electrochemical gradient; raised presynaptic [Na+] eliminates the driving force for reuptake
4. Simultaneous multi-transmitter inhibition: Serotonin, dopamine, norepinephrine, GABA, and glutamate reuptake all inhibited — unlike any pharmaceutical antidepressant
5. PXR activation → CYP3A4/P-gp induction: Hyperforin is a potent PXR (Pregnane X Receptor) ligand → PXR/RXR heterodimerisation → binds PXREs in CYP3A4 and MDR1/ABCB1 promoters → 3–8-fold induction of CYP3A4 expression and 2–4-fold induction of P-gp

Pleiotropic Effects

Clinical Use & Dosing

Extract standardisation matters critically: LI 160 (standardised to 0.3% hypericin) is the most studied preparation in older trials; WS 5570 (0.3% hypericin + 3% hyperforin) is pharmacologically superior and preferred in mechanistically-informed trials. WS 5573 (low-hyperforin variant) was less effective in one head-to-head RCT, directly supporting hyperforin as the primary active constituent. Doses across preparations are not interchangeable.

Key Studies

Safety & Drug Interactions

• Ciclosporin / tacrolimus — ABSOLUTE CONTRAINDICATION: Multiple case series document acute transplant rejection from SJW-induced ciclosporin plasma level reduction; all transplant patients must be screened for SJW use
• HIV antiretrovirals (indinavir, nevirapine, efavirenz) — AVOID: CYP3A4/P-gp induction reduces plasma levels → virological failure documented in clinical case reports; HIV therapy must not be combined with SJW
• Oral contraceptive pill (ethinylestradiol) — SWITCH CONTRACEPTION: Reduced OCP plasma levels → contraceptive failure and breakthrough bleeding; women must use alternative contraception during SJW use and for 2 weeks after stopping
• Warfarin — MONITOR INR CLOSELY: CYP2C9/3A4-mediated warfarin metabolism increases → reduced INR → thrombosis risk; dose increases likely needed; close monitoring essential
• SSRIs / SNRIs / MAOIs / tramadol — SEROTONIN SYNDROME RISK: Additive serotonergic effects via TRPC6-mediated SERT inhibition + hypericin MAO-A inhibition; case reports of agitation, myoclonus, diaphoresis, hyperthermia; FDA warns against combination without supervision
• Digoxin (P-gp substrate): P-gp induction reduces digoxin plasma levels — monitor drug levels and therapeutic effect
• Irinotecan / imatinib: CYP3A4 induction reduces antineoplastic plasma levels → compromised cancer therapy efficacy; avoid in oncology patients receiving these agents
• Photosensitivity (hypericin-mediated): UV-A/B sensitisation; fair-skinned individuals should limit sun exposure during treatment; avoid sunbeds
• Discontinuation: Tapering recommended for patients on maintenance therapy to avoid rebound depressive symptoms; CYP3A4 induction persists for 1–2 weeks after stopping

Connections

References

• Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008;(4):CD000448. doi:10.1002/14651858.CD000448.pub3
• Madabushi R, Frank B, Drewelow B, et al. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol. 2006;62(3):225-33. doi:10.1007/s00228-006-0096-z
• Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's Wort in major depression. JAMA. 2001;285(15):1978-86. doi:10.1001/jama.285.15.1978
• Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's Wort) in major depressive disorder. JAMA. 2002;287(14):1807-14. doi:10.1001/jama.287.14.1807
• Müller WE. Current St. John's wort research from mode of action to clinical efficacy. Pharmacol Res. 2003;47(2):101-9. doi:10.1016/S1043-6618(02)00266-9
• Evans WC. Trease and Evans' Pharmacognosy. 16th ed. Saunders; 2009.